Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of “Buy” by Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have received an average recommendation of “Buy” from the fifteen analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $102.00.

A number of equities research analysts have recently commented on MIRM shares. JMP Securities set a $95.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 5th. Raymond James Financial reissued a “strong-buy” rating and issued a $110.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Morgan Stanley increased their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Finally, Evercore ISI boosted their target price on Mirum Pharmaceuticals from $89.00 to $94.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th.

Mirum Pharmaceuticals Trading Down 1.4%

NASDAQ MIRM opened at $91.05 on Monday. Mirum Pharmaceuticals has a 12 month low of $36.88 and a 12 month high of $93.70. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The stock’s fifty day moving average price is $75.05 and its 200-day moving average price is $69.41. The stock has a market cap of $4.68 billion, a P/E ratio of -105.87 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. During the same quarter in the previous year, the firm earned ($0.30) EPS. Mirum Pharmaceuticals’s quarterly revenue was up 47.1% compared to the same quarter last year. As a group, equities analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. MCF Advisors LLC raised its stake in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals during the third quarter valued at $33,000. Comerica Bank lifted its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. Quarry LP purchased a new position in Mirum Pharmaceuticals in the third quarter worth about $41,000. Finally, CWM LLC grew its stake in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.